No products in the cart.
TRBV12-3: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It’s the GeneMedi’s summary page for Target/Biomarker Introduction of TRBV12-3. The page also collects GeneMedi’s different modalities and formats products for TRBV12-3 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the TRBV12-3 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
Predicted to be involved in cell surface receptor signaling pathway. Predicted to be part of T cell receptor complex. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]
|
Target ID |
GM-MP1868
|
|
Target Name |
TRBV12-3
|
|
Gene ID |
28577
|
|
Gene Official Name |
TRBV12-3
|
|
Gene Alias |
TCRBV12S3, TCRBV8S1, TRBV123
|
|
Protein Sub-location |
Transmembrane Protein
|
|
Category |
|
Anti-TVBL3/ TRBV12-3/ TCRBV12S3 antibody for FACS & in-vivo assay| GMab
Pre-made anti-TRBV12-3 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TRBV12-3 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Filters
Sort results
Reset
Apply
Cat No. | Antibody Name | Format | Classified by tag | Order
|
|---|---|---|---|---|
Anti-TRBV12-3 monoclonal antibody |
mab |
FACS/Biofunctional Antibody |
